340B and Pharmaceutical Access

340B and Pharmaceutical Access

The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.

340B Helps Kids

This resource provides information and statistics on the 340B program.

CHA Submits Drug Shortages Hearing Statement for the Record

CHA submitted a statement for a House Energy and Commerce hearing to highlight how children’s needs must be prioritized when strengthening the pediatric drug supply chain.

May 12, 2023

Fiscal Year 2023 Omnibus Summary

This detailed summary of the FY 2023 Omnibus focuses on those provisions of most interest to children’s hospitals.

Jan. 13, 2023

VALID Act Letter

We sent a letter to Senate HELP Committee leadership to highlight the implications of the VALID Act.

June 15, 2022

Letter to FDA on Critical Shortages Affecting Pediatric Care

CHA sent a letter to the FDA asking the agency to address two critical shortages affecting children and families.

May 11, 2022

House Healthy Future Task Force Requests for Information Responses

CHA has submitted responses to several RFIs from the House Healthy Future Task Force.

March 11, 2022

COVID-19 Congressional Relief Legislation

Multiple packages for COVID-19 relief have passed to date. Read more about them here.

Jan. 27, 2022

340B Program Talking Points

The 340B program supports children's hospitals in their mission to serve low-income, uninsured and under-insured patients.

May 01, 2021

340B Drug Pricing Program Overview

The 340B Drug Pricing Program was created by Congress to help certain health care providers purchase outpatient drugs at a reduced price.

June 20, 2018

Key Provisions of the Affordable Care Act for Children

The ACA includes important provisions to make children's health care more age-appropriate, affordable, accessible and timely.

July 01, 2017

Contact Us

For more information, connect with us.

(202) 753-5333

For the Record

View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.